Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial US$ 24.31 Min. order: 1 piece ★★★★★ 4.1 (196 reviews) Sold : Login>>
Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants - Gabe - 2024 - Diabetes, Obesity and Metabolism US$ 21.97 Min. order: 1 piece ★★★★★ 4.2 (112 reviews) Sold : Login>>
Copper Peptide 10 GHK-Cu 5 AHK-Cu Hair Growth Serum US$ 25.15 Min. order: 1 piece ★★★★★ 4.2 (253 reviews) Sold : Login>>
Targeting the weight within: obesity pharmacotherapy in cardiovascular disease US$ 21.65 Min. order: 1 piece ★★★★★ 4.3 (167 reviews) Sold : Login>>
Novo Nordisk's latest trial results for its next-generation obesity drug CagriSema disappointed investors by failing to show superior outcomes to existing drugs. ➡️ CagriSema, which includes a nascent form of weight loss US$ 27.53 Min. order: 1 piece ★★★★★ 4.6 (39 reviews) Sold : Login>>